Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
OTC Drugs

New Products In Brief

This article was originally published in The Tan Sheet

  • News
  • The Tan Sheet

Executive Summary

Bausch + Lomb updates AREDS formula: Due to hit shelves in May, PreserVision Eye Vitamin and Mineral Supplement AREDS2 formula aims to support eye health and prevent age-related macular degeneration. Bausch + Lomb says April 9 the PreserVision line extension includes omega-3 fatty acids and the carotenoids lutein and zeaxanthin, as used in the ongoing second Age-Related Eye Disease Study. The Madison, N.J., firm suggests a retail price of $29.99 for 60 soft gels. The results from the original National Institutes of Health-sponsored Age-Related Eye Disease Study were released in 2001; AREDS2 completed patient enrollment in 2008 (1"The Tan Sheet" Nov. 3, 2008)

You may also be interested in...



In Brief

Pfizer promotes Advil Congestion Relief

In Brief

Pfizer promotes Advil Congestion Relief

In Brief

Pfizer promotes Advil Congestion Relief

Table

View full table

Topics

Tags:
OTC Drugs
Latest Headlines

Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification

US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios

FTC Early Findings In PBM Investigation Coming By Mid-Summer, Chair Kahn Says

New EU Filings

See All
UsernamePublicRestriction

Register

PS104042

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By